Studion Promotes Brian Harrington to General Manager of Life Sciences Business to Drive Growth of eClinical Services
Studion, a technology services company specializing in the design, development, and delivery of digital experiences for the Learning and Life Sciences sectors, has announced the promotion of Brian Harrington to General Manager of its Life Sciences business unit. The appointment reflects the company’s continued investment in expanding its eClinical capabilities and supporting pharmaceutical, biotechnology, and medical device organizations with technology-driven clinical trial solutions.
In his new leadership role, Harrington will oversee the overall strategy, operational execution, business growth, and service delivery for Studion’s Life Sciences division. He will also guide the company’s expanding portfolio of end-to-end eClinical services, helping clients streamline clinical development programs, improve operational efficiency, and accelerate the delivery of new therapies to patients.
The promotion comes at a time when the life sciences industry continues to embrace digital transformation, with increasing demand for scalable, patient-centric, and regulatory-compliant eClinical technologies capable of supporting increasingly complex clinical trials.
Strengthening Leadership During Industry Growth
Clinical research has undergone significant technological evolution over the past decade, with digital platforms becoming central to nearly every aspect of modern clinical trial management.
From electronic data capture and patient-reported outcomes to remote monitoring and digital consent processes, technology has transformed how sponsors design, conduct, and manage clinical studies.
As pharmaceutical companies pursue increasingly global, decentralized, and data-intensive clinical trials, demand for experienced technology partners has continued to rise.
Studion’s decision to appoint Brian Harrington as General Manager reflects its commitment to strengthening leadership within this rapidly expanding market while continuing to scale its service offerings for clients across the life sciences industry.
The company believes Harrington’s combination of commercial, operational, and customer success experience positions him well to lead the next phase of growth for the business unit.
Extensive Experience in Clinical Trial Technology
Harrington brings substantial expertise in the clinical research technology sector, with experience spanning customer success, operational leadership, commercial development, and strategic partnership management.
Throughout his career, he has worked closely with organizations across the digital health ecosystem, helping develop technology solutions that support clinical trial sponsors, contract research organizations (CROs), and technology providers.
Before assuming his new position, Harrington served in Studion’s Commercial Development organization, where he played a key role in strengthening customer relationships while helping shape new service offerings aligned with evolving industry requirements.
His work focused on identifying opportunities to improve client experiences while expanding the company’s capabilities in response to changing clinical research needs.
This combination of commercial insight and operational expertise provides a strong foundation for leading Studion’s Life Sciences business as demand for digital clinical trial solutions continues to grow.
Leading Strategy and Business Growth
As General Manager, Harrington will be responsible for overseeing multiple aspects of Studion’s Life Sciences operations.
His responsibilities will include:
- Strategic planning
- Business development
- Operational leadership
- Service delivery
- Customer success
- Organizational growth
- Expansion of managed service offerings
He will also lead initiatives designed to strengthen Studion’s position as a trusted technology partner for organizations conducting clinical research.
A key focus of his leadership will involve helping clients accelerate study timelines while maintaining regulatory compliance and high-quality clinical data.
By integrating technology expertise with operational excellence, Studion aims to simplify clinical trial execution and improve efficiency across every stage of study development.
Expanding End-to-End eClinical Services
Studion has established itself as a platform-agnostic provider of eClinical services, supporting clients across multiple technology environments rather than limiting services to a single software platform.
This flexible approach enables the company to collaborate with pharmaceutical sponsors, biotechnology companies, CROs, and technology vendors using a wide variety of clinical research systems.
Its end-to-end services encompass the design, configuration, testing, implementation, validation, and maintenance of digital clinical trial solutions.
These services help sponsors manage increasingly complex studies while ensuring compliance with evolving regulatory standards.
Under Harrington’s leadership, the company intends to continue expanding these capabilities while introducing new service models designed to improve operational efficiency for customers.
Supporting Modern Clinical Trials
Digital technologies have become essential components of contemporary clinical research.
Modern studies frequently rely on electronic systems to collect, manage, and analyze clinical data while improving participant engagement and reducing administrative burdens.
Studion’s Life Sciences business supports several important eClinical technologies.
Among its core capabilities are:
Electronic Clinical Outcome Assessments (eCOA)
Electronic Clinical Outcome Assessment solutions allow participants to report symptoms, treatment responses, and quality-of-life information using digital devices instead of traditional paper questionnaires.
These systems improve data accuracy, reduce transcription errors, and provide investigators with real-time access to patient-reported information.
Electronic Consent (eConsent)
Electronic informed consent platforms modernize one of the most important components of clinical research.
Rather than relying exclusively on paper documentation, eConsent systems provide interactive educational materials that improve participant understanding while streamlining documentation and regulatory compliance.
Electronic Data Capture (EDC)
Electronic Data Capture systems serve as the central repository for clinical trial data.
These platforms allow investigators to securely collect, validate, and manage clinical information throughout study execution while supporting regulatory submissions and statistical analyses.
According to the company, Studion has designed, built, and tested more than 2,000 eCOA, eConsent, and EDC solutions spanning numerous therapeutic areas.
This extensive project experience provides the organization with broad expertise across diverse clinical research programs.
Growing Demand for Patient-Centered Technologies
The promotion comes during a period of continued growth in digital clinical research.
Healthcare organizations increasingly recognize the importance of developing patient-centered technologies that simplify participation while improving the overall clinical trial experience.
Electronic platforms reduce paperwork, improve communication, support remote participation, and facilitate decentralized clinical trials that enable patients to participate without frequent visits to research centers.
These capabilities have become especially valuable as sponsors seek to improve recruitment, increase participant retention, and collect higher-quality clinical data.
At the same time, regulatory agencies continue encouraging adoption of digital technologies capable of improving both study quality and patient engagement.
Studion expects these trends to continue driving demand for comprehensive eClinical technology services.
Expanding Managed Service Offerings
One of Harrington’s primary areas of focus will be expanding Studion’s managed services portfolio.
While traditional staff augmentation remains an important part of the company’s business, managed services provide clients with more comprehensive operational support throughout the clinical trial lifecycle.
Studion’s managed service offerings include specialized support for:
- Study start-up
- Study maintenance
- Ongoing operational management
- Platform support
- Technology optimization
These services enable clients to outsource selected operational responsibilities while improving resource utilization and reducing internal administrative burdens.
According to the company, managed services also improve financial predictability by allowing organizations to better forecast operational costs throughout study execution.
This approach may be particularly attractive for biotechnology companies and emerging pharmaceutical organizations seeking greater operational flexibility while controlling expenses.
Helping Accelerate Drug Development
Efficient clinical trial execution remains one of the most important factors influencing the speed at which new therapies reach patients.
Delays during study start-up, technology implementation, data collection, or ongoing maintenance can significantly extend development timelines while increasing overall costs.
Studion’s technology services are designed to minimize these challenges by providing experienced teams capable of supporting clients throughout the entire clinical development process.
Improved operational efficiency may ultimately reduce study delays while enabling sponsors to advance investigational therapies more rapidly toward regulatory review.
As clinical trials become increasingly complex, technology partners capable of delivering integrated support across multiple digital platforms play an increasingly important role in successful study execution.
Leadership Highlights Company Vision
Studion Chief Executive Officer Furqan Nazeeri described Harrington as an ideal leader for the company’s expanding Life Sciences organization.
He highlighted Harrington’s understanding of the technological complexity involved in modern clinical trials and his ability to develop innovative solutions addressing those challenges.
According to Nazeeri, the promotion reflects Studion’s ongoing commitment to serving as a trusted strategic partner for life sciences organizations while continuing to expand its eClinical technology expertise.
He also emphasized the company’s growing investment in managed services supporting study start-up and ongoing study maintenance.
Focus on Scalable Client Solutions
Harrington expressed enthusiasm about leading the Life Sciences business during a period of rapid industry transformation.
He noted that life sciences organizations increasingly seek strategic technology partners capable of delivering scalable and predictable operational support.
While recognizing the continued importance of staff augmentation services, Harrington emphasized his excitement regarding the expansion of managed service offerings.
He believes these solutions help eClinical providers improve both financial and operational predictability while reducing costs and enabling more efficient clinical trial execution.
Ultimately, these improvements contribute to the broader industry goal of bringing innovative therapies to patients more quickly.
Brian Harrington’s promotion to General Manager marks an important milestone in Studion’s continued expansion within the rapidly evolving eClinical technology market.
With extensive experience spanning customer success, commercial development, operational leadership, and clinical trial technology, Harrington is well positioned to guide the company’s Life Sciences business through its next phase of growth.
As pharmaceutical companies, biotechnology organizations, and CROs continue embracing digital transformation, demand for comprehensive eClinical services is expected to remain strong. Through its platform-agnostic approach, extensive experience delivering more than 2,000 digital clinical solutions, and growing portfolio of managed services, Studion aims to help clients streamline study operations, improve efficiency, and accelerate the development of life-changing therapies.
Under Harrington’s leadership, the company plans to further strengthen its role as a strategic technology partner supporting modern clinical research while expanding innovative service offerings that address the evolving needs of the global life sciences industry.
About Studion
Studion is a technology services firm that creates engaging digital experiences in Learning and the Life Sciences. Studion’s Life Sciences business unit specializes in supporting eClinical technology across the clinical trial lifecycle, including managed services and staff augmentation engagement models.